NASDAQ$NVCT
Nuvectis Pharma Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Reported financial results for the second quarter of 2023 and provided an update on recent pipeline progress.
Nuvectis Pharma reported its Q2 2023 financial results, highlighting progress in its NXP800 and NXP900 development programs. The company initiated a Phase 1b clinical trial for NXP800 and expects to initiate a Phase 1a dose escalation study for NXP900 this quarter. Nuvectis significantly strengthened its financial position, ending the quarter with approximately $24.6 million in cash, expected to support planned operations into H1 2025.
- Initiated a Phase 1b clinical trial for NXP800 in patients with platinum resistant, ARID1a-mutated ovarian carcinoma, with a preliminary data update expected in Q1 2024.
- Preclinical data supports the expansion of the NXP800 clinical program into additional potential target indications, such as cholangiocarcinoma.
- The FDA cleared the IND application for NXP900, and the Phase 1a dose escalation study is expected to begin this quarter.
- Cash, cash equivalents, and short-term investments were $24.6 million as of June 30, 2023, expected to support planned operations into H1 2025.
Headline financials
Revenue & EPS history
Nuvectis Pharma · Revenue · Quarterly
$100
Forward guidance
The company expects to support planned operations into H1 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+2.4%
Avg return
Earnings day
+7.2%
Avg return
5 days after
-3.7%
Avg return
30 days after
65%
13 / 20 earnings
Positive
+29.2%
Q3 2024
Best reaction
-14.9%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +9.4% | +31.6% | +8.8% | |
| Q4 2026 | +0.5% | +0.2% | +3.3% | |
| Q3 2025 | -7.9% | -3.5% | +6.1% | |
| Q2 2025 | -5.4% | -17.7% | -10.6% | |
| Q1 2025 | +6.4% | +8.3% | -9.4% | |
| Q4 2024 | -5.8% | -9.1% | +31.1% | |
| Q3 2024 | +29.2% | +71.3% | -24.6% | |
| Q1 2024 | -14.9% | -15.3% | -13.6% | |
| Q4 2023 | -4.5% | -0.4% | -25.1% | |
| Q3 2023 | -7.9% | -6.6% | -8.4% | |
| Q2 2023 | +1.4% | +1.1% | -7.0% | |
| Q1 2023 | +5.8% | +6.3% | +14.0% | |
| Q4 2022 | -7.1% | -9.5% | +9.2% | |
| Q3 2021 | +0.9% | -3.5% | +7.7% | |
| Q3 2022 | +0.9% | -3.5% | +7.7% | |
| Q2 2021 | +1.1% | +10.1% | -0.6% | |
| Q2 2022 | +2.6% | -3.0% | -3.7% | |
| Q1 2021 | +18.8% | +28.8% | -24.4% | |
| Q4 2021 | +18.8% | +33.6% | -15.6% | |
| Q1 2022 | +5.4% | +25.2% | -19.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro